MARKET

RLYB

RLYB

Rallybio Corp
NASDAQ
8.04
-0.18
-2.19%
Closed 19:47 03/30 EDT
OPEN
8.35
PREV CLOSE
8.22
HIGH
8.37
LOW
7.90
VOLUME
58.19K
TURNOVER
0
52 WEEK HIGH
11.49
52 WEEK LOW
1.761
MARKET CAP
42.53M
P/E (TTM)
-5.0411
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RLYB last week (0323-0327)?
Weekly Report · 1d ago
Weekly Report: what happened at RLYB last week (0316-0320)?
Weekly Report · 03/23 10:09
Rallybio CVRs Carry High Risk of Expiring Worthless Amid Uncertain Asset Monetization
TipRanks · 03/18 06:00
Weekly Report: what happened at RLYB last week (0309-0313)?
Weekly Report · 03/16 10:09
Weekly Report: what happened at RLYB last week (0302-0306)?
Weekly Report · 03/09 10:09
Rallybio Completes Key FNAIT Risk Study, Laying Groundwork for Future Market Moves
TipRanks · 03/06 16:32
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
Barchart · 03/04 10:53
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 03/02 21:06
More
About RLYB
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.

Webull offers Rallybio Corp stock information, including NASDAQ: RLYB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RLYB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RLYB stock methods without spending real money on the virtual paper trading platform.